Clinical Trials on Chronic Myeloid Leukaemia

Total 40594 results

Centre Hospitalier Universitaire de Besancon

Completed

Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) (CAR-LMC)

Chronic Myeloid Leukemia

France
M.D. Anderson Cancer Center
Novartis

Completed

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myeloid, Chronic

United States
Pfizer

Completed

Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects

Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)

Singapore
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Guangdong Provincial People's Hospital

Not yet recruiting

Treatment Free Remission (TFR) in CML Patients （CML-CP）Study

Chronic Myeloid Leukemia | Treatment-free Remission
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Juvenile Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Childhood Acute Lymphoblastic Leukemia | Prolymphocytic Leukemia | Hairy Cell Leukemia | Acute Undifferentiated Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Childhood Acute Myeloid... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Dartmouth-Hitchcock Medical Center

Active, not recruiting

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Lymphoma | Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Myelofibrosis | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplasia | Myeloproliferative Disorder | Plasma Cell Disorder

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
University of Milano Bicocca

Recruiting

Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation

Chronic Myeloid Leukemia

Italy, Canada, Germany, Spain
Fusion Pharma LLC
Data Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation Center

Unknown

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid Leukemia

Russian Federation
Norwegian University of Science and Technology

Completed

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006)

Chronic Myeloid Leukemia

Sweden, Finland, Norway
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

Chronic Myeloid Leukemia

China
Università degli Studi di Brescia

Completed

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy (INTERIM0407)

Chronic Myeloid Leukemia

Italy
Seoul St. Mary's Hospital
Ministry of Health & Welfare, Korea

Unknown

Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib

Chronic Myeloid Leukemia | Imatinib | Complete Molecular Response

Korea, Republic of
Technische Universität Dresden
Nordic Society for Pediatric Hematology and Oncology; Uniuversity of Genua,... and other collaborators

Unknown

Registration of Children With CML and Treatment With Imatinib (CML-paed II)

Myeloid Leukemia, Chronic

Germany
European Society for Blood and Marrow Transplantation
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia (Dasatinib)

Chronic Myeloid Leukemia

Switzerland, United Kingdom, France, Germany
Bristol-Myers Squibb

Terminated

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Leukemia

United States
Novartis Pharmaceuticals

Recruiting

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (ASSURE-3)

Chronic Myeloid Leukemia

France
Fundaleu

Recruiting

Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase (AST)

CML

Argentina
Poitiers University Hospital
University Medical Center Groningen; Imperial College London; University of Liege and other collaborators

Recruiting

International Chronic Myeloid Leukemia Pediatric Study (ICMLPed)

Chronic Myeloid Leukemia

Denmark, China, Germany, Australia, Belgium, Brazil, Chile, Croatia, Czechia, France, Greece, Japan, Lebanon, Poland, Spain, Turkey, Austria, Belarus, Netherlands, Slovakia
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Incyte BioSciences France

Completed

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Chronic Myeloid Leukemia

France
Bristol-Myers Squibb

Completed

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (DIM Vidaza)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Leukemia, Myeloid, Chronic

Israel
Bristol-Myers Squibb

Completed

Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)

Chronic Myeloid Leukemia
Asan Medical Center

Active, not recruiting

HCT With PTCy in Higher-risk MDS

Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)

Korea, Republic of
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome

United States
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Clinical Hub for Interventional Research (CHOIR)
The University of New South Wales; Australian National University

Recruiting

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Myelogenous Leukemia, Chronic, Chronic Phase

United States
Cancer Trials Ireland

Completed

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States, Ireland, Israel, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
University of California, Irvine
United States Department of Defense

Active, not recruiting

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, Refractory

United States
Novartis Pharmaceuticals

Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Myeloid Leukemia, Philadelphia Positive

Korea, Republic of, Germany, France, United States, Greece, Hungary, Italy, Japan, Poland, Russian Federation, Thailand, Turkey, China, Netherlands
Renato Melaragno

Unknown

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)

Brazil
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Everett Meyer
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative Syndrome

United States
Kirby Institute
Celgene

Active, not recruiting

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
Ascentage Pharma Group Inc.

Recruiting

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Myeloid Leukemia | Chronic Myeloid Leukemia | Philadelphia Positive Acute Lymphoblastic Leukemia | Leukemia, Myeloid, Chronic | B Cell Precursor Type Acute Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
University Hospital, Bordeaux

Recruiting

CML Pediatric ITK Response According to Molecular Identification at Diagnosis (CML Piramid)

Chronic Myeloid Leukemia

France
Novartis Pharmaceuticals

Completed

Special Drug Use-results Surveillance of Scemblix Tablets

Chronic Myeloid Leukemia

Japan
Novartis Pharmaceuticals

Active, not recruiting

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop)

Chronic Myeloid Leukemia

Japan, Germany, Canada, Australia, France, Israel, Spain, United States, Greece, United Kingdom, Korea, Republic of, Brazil, Russian Federation, Argentina, Poland, Singapore, Belgium, Mexico
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
Assiut University

Completed

Effect of Pharmacogenetics on Imatinib Plasma Level and Response

Chronic Myeloid Leukemia

Egypt
Polish Adult Leukemia Group

Completed

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis

Chronic Myeloid Leukemia

Clinical Trials on Chronic Myeloid Leukaemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations